Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments discussed: GT 20029, Pyrilutamide, Minoxidil, Finasteride, and Dutasteride. Some believe Dutasteride will replace Finasteride.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.

The user is optimistic about hair regrowth after 3 months of using 1mg oral finasteride daily, topical minoxidil twice daily, and microneedling once a week. They report improvements in hair density and color, particularly at the crown and fringe.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

A user who didn't respond well to minoxidil and finasteride is considering the role of IGF-1 in hair loss treatment effectiveness. They discuss the potential of using HGH to improve hair growth and other health issues, referencing several sources that suggest IGF-1 levels may influence hair loss and treatment response.

Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The user switched from minoxidil to a homemade 2-deoxy-d-ribose gel and noticed no hair fall after two weeks, despite stopping minoxidil. The gel includes water, 2-deoxy-d-ribose, vegetable glycerine, 2-phenoxyethanol, sodium alginate, and rosemary oil, and the user reports healthier-feeling hair.

After jaw surgery caused intense hair shedding and scalp itch, using pyrilutamide significantly reduced these symptoms. It's suggested to test pyrilutamide for authenticity before use, despite positive personal experience with the product from MV Supplements.

A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

The user experienced hair regrowth using finasteride, biotin, folic acid, vitamin D3, and microneedling, despite initial shedding. Vitamin D3 deficiency caused hair loss and insomnia.

User reports hair loss improvement with twice-weekly 0.25mg Fin, twice-weekly Min, weekly 0.5mm microneedling, and daily massages. Unconventional regimen contradicts typical advice but may reduce side effects.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

Shedding for a few months is normal when starting 1mg finasteride and 2.5mg minoxidil. It indicates the treatments are working, and hair growth should stabilize over time.

Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.

A 19-year-old male shared his 3-month hair regrowth progress using finasteride, minoxidil, and microneedling, with noticeable improvement. He uses 1mg oral finasteride daily, 5% minoxidil foam twice a day after day 80, and microneedles with a 1.5mm derma stamp every 1-2 weeks.

The user reported progress in hair regrowth after three months of using oral finasteride and minoxidil foam, despite initial doubts. They noted no side effects, a clean diet, regular weightlifting, and additional supplements.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

The user experienced noticeable hair thickening and new growth after two months using a topical solution of minoxidil and finasteride. Continued improvement is expected, with potential for a full head of hair after further treatment and possibly a transplant.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.